23andMe Holding Co. (ME )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ME
- Company 23andMe Holding Co.
- Price $0.61
- Changes Percentage 100
- Change 0.61
- Day Low $0.61
- Day High $0.61
- Year High $12.76
- Year Low $0.48
- Market Cap $15,307,810
- Price Avg 50 EMA (D) $1.68
- Price Avg 200 EMA (D) $4.38
- Exchange NASDAQ
- Volume 29,751,445
- Average Volume 4,101,922
- Open $0.61
- Previous Close $0.61
- EPS -17.39
- PE -0.03
- Earnings Announcement 2025-01-28 22:15:00
- Shares Outstanding $25,247,914
Company brief: 23ANDME HOLDING CO. (ME )
- Healthcare
- Medical - Diagnostics & Research
- Ms. Anne Wojcicki
- https://www.23andme.com
- US
- N/A
- 11-23-2020
- US90138Q1085
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.